Harvard Bioscience (HBIO) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Harvard Bioscience (HBIO) over the past year, gaining 101.8% versus a gain of 84.8%. Over five years, NAUT leads with a -68.1% price change compared with -88.1% for HBIO. Nautilus Biotechnology is the larger company by market cap ($231.6 million vs $37.0 million), about 6.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HBIO | NAUT |
|---|---|---|
| Share price | $8.13 | $1.82 |
| Market cap | $37.01M | $231.60M |
| 1-day change | -4.35% | -7.14% |
| YTD return | +21.34% | -6.67% |
| 1-year return | +84.77% | +101.77% |
| 5-year return | -88.11% | -68.13% |
| Forward P/E | 12.60 | — |
| EPS (TTM) | $-2.31 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.40 | $4.31 |
| 52-week low | $3.80 | $0.82 |
| Distance from 52-week high | -13.51% | -57.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -7.75% | +110.44% |
| Average volume | 17.98K | 2.66M |
| Shares outstanding | 4.55M | 127.26M |
| Employees | 316 | 127 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nautilus Biotechnology is about 6.3 times larger than Harvard Bioscience by market value ($231.60M vs $37.01M).
- NAUT has outperformed HBIO by 17.0 percentage points over the past year.
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
HBIO vs NAUT FAQ
Which is bigger, Harvard Bioscience or Nautilus Biotechnology?
Nautilus Biotechnology (NAUT) is larger, with a market capitalization of $231.60M compared with $37.01M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, HBIO or NAUT?
NAUT returned +101.77% over the past 12 months, compared with +84.77% for HBIO (price return, excluding dividends). Past performance does not predict future results.
Are Harvard Bioscience and Nautilus Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.